Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Pancreatic Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Lung Neoplasms 2Leukemia, Myeloid, Acute 2Stomach Neoplasms 1Sarcoma, Myeloid 1Recurrence 1Pancreatic Ductal Adenocarcinoma 1Ovarian Neoplasms 1Myelodysplastic Syndromes 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia 1Esophageal Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Hepatocellular 1Burkitt Lymphoma 1Breast Neoplasms 1Adenocarcinoma of Lung 1Adenocarcinoma 1

Interventions

Carboplatin 36Pemetrexed 28Bevacizumab 26Cisplatin 24Paclitaxel 22Gemcitabine 20Radiotherapy 18Docetaxel 18Erlotinib Hydrochloride 15Gefitinib 11pembrolizumab 6Cetuximab 6capmatinib 5Surgical Procedures, Operative 5Radiosurgery 5aflutinib 4Vinorelbine 4Taxes 4Platinum 4Nivolumab 4Metformin 4pegfilgrastim 3durvalumab 3ceritinib 3apatinib 3Sorafenib 3Radiation 3Neoadjuvant Therapy 3Magnetic Resonance Spectroscopy 3tislelizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Adenocarcinoma of Lung × devimistat × Clear all
NCT05733000 2023-03-10

CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors

Northwestern University

Phase 2 Recruiting
94 enrolled
GastrointestinalGenitourinaryGynecologicThoracic

Adenocarcinoma of Lung, Carcinoma, Transitional Cell, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡